european medicines agency glp-1 vision loss recommendation november 2025 EU actions to tackle shortages of receptor agonists The expanding landscape of GLP-1

(F or example, see in Table 1 the status of indications for semaglutide.) This broadening of indications has opened new patient segments and strengthened clinical appeal

We also analyzed PLIN2 data from 200 subjects with histologically proven MASH with or without T2DM enrolled in the BRAVES RCT (NCT03524365)

10.1152/ajpendo.00503.2002

Our data reveal that while GLP-1R knockdown in the LS does not alter basal food intake or body weight, TeNT-mediated inactivation of these neurons promotes food intake and weight gain on a high-fat diet

The best time to build routines is during treatment, when cravings are lower and appetite feels more manageable